ArticleAfrican journal of primary health care & family medicine2025
Predictors of drug-resistant TB outcomes: Body mass index, HIV, and comorbidities.
Article in African journal of primary health care & family medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Predictors of Treatment Outcomes Among HIV-Positive Patients with Drug-Resistant Tuberculosis in Rural Eastern Cape, South Africa: A Retrospective Cohort Study.International journal of environmental research and public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe success rates for treating drug-resistant tuberculosis (DR-TB) in programmatic settings have been unsatisfactory. By identifying the factors that predict treatment outcomes, we can implement effective corrective measures that will significantly enhance patient management and improve results for those with DR-TB.
aimThis study aimed to investigate predictive factors influencing treatment outcomes among DR-TB patients, focusing on the combined effects of body mass index (BMI), human immunodeficiency virus (HIV) status, comorbidities, socioeconomic factors, substance use and DR-TB type.
settingThe study was conducted in rural Eastern Cape, South Africa.
methodsThis retrospective cohort study was designed to utilise logistic regression models on data from 200 patient medical records. We examined variables including BMI, HIV co-infection, comorbidities (e.g. diabetes, hypertension), income, substance use and DR-TB classifications (multidrug-resistant, rifampicin-resistant, pre-extensively drug-resistant, extensively drug-resistant).
resultsKey findings indicate a weak association between lower BMI and reduced treatment success (odds ratio [OR]: 0.92, 95% confidence interval [CI]: 0.81-1.05). HIV-positive status was marginally associated with lower treatment success (OR: 0.89, 95% CI: 0.75-1.12), while income level and substance use emerged as stronger predictors (e.g. substance use OR: 0.72, 95% CI: 0.60-0.88). Among DR-TB types, extensively drug-resistant tuberculosis patients exhibited the poorest outcomes (OR: 0.55, 95% CI: 0.40-0.75). The multivariate model achieved an accuracy of 63.1%, suggesting limited predictive power of BMI and HIV alone and highlighting the significant influence of comorbidities, socioeconomic status and behavioural factors.
conclusionThese findings underscore the importance of a multidimensional approach in improving DR-TB treatment outcomes through tailored clinical and social interventions.Contribution: The study noted limited connections between DR-TB and various comorbidities. It highlights the necessity of managing coexisting conditions in DR-TB patients because of their significant impact on treatment outcomes. Customised interventions are essential for those with severe or complex comorbidities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.